Comments on: Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

Comments on: Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility https://thegbm.com/johnson-johnsons-darzalex-daratumumab-subcutaneous-based-regimen-receives-positive-chmp-opinion-for-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibi/ Business news, opinion, reviews, interviews Fri, 28 Feb 2025 13:01:00 +0000 hourly 1 https://wordpress.org/?v=6.7.2